

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2019	2018	2019	2018
Grant and collaboration revenue	\$ 210	\$ 93	\$ 574	\$ 315
Operating expenses:				
Research and development	451	372	1,007	859
General and administrative	413	359	923	717
	<u>864</u>	<u>731</u>	<u>1,930</u>	<u>1,576</u>
Loss from operations	(654)	(638)	(1,356)	(1,261)
Other income (expense), net	-	1	-	2
Net loss	<u>\$ (654)</u>	<u>\$ (637)</u>	<u>\$ (1,356)</u>	<u>\$ (1,259)</u>
Loss per common share	<u>\$ (1.01)</u>	<u>\$ (2.05)</u>	<u>\$ (2.37)</u>	<u>\$ (4.50)</u>

GEOVAX LABS, INC.
Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	June 30, 2019	Dec. 31, 2018
Assets:		
Cash and cash equivalents	\$ 216	\$ 260
Other current assets	104	360
Total current assets	<u>320</u>	<u>620</u>
Property, net	12	11
Other assets	11	11
Total assets	<u>\$ 343</u>	<u>\$ 642</u>
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 1,639	\$ 1,624
Note payable, net of current portion	32	40
Stockholders' equity (deficiency)	(1,328)	(1,022)
Total liabilities and stockholders' equity (deficiency)	<u>\$ 343</u>	<u>\$ 642</u>
Common shares outstanding	814	438